Observational studyDiabetes, obesity & metabolism2025
Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod® 5) in adults with type 1 diabetes.
Observational study in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Looking Beyond Glycaemic Control: Real-World 12-Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Barriers and Enablers to Diabetes Technologies Use Among Individuals With Type 1 Diabetes: A Scoping Review.Diabetes, obesity & metabolism · 2026Article
- Discordant real-world glycaemic outcomes with Omnipod™ 5 and MiniMed™ 780G in adults with type 1 diabetes: Why validated measures matter.Diabetes, obesity & metabolism · 2026Article
- Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systems.Diabetologia · 2026Review
- Hybrid closed-loop systems in UK type 1 diabetes care: National survey of healthcare professional awareness, confidence, and training needs.Diabetes, obesity & metabolism · 2025Article
- Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod® 5) in adults with type 1 diabetes.Diabetes, obesity & metabolism · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsWe aimed to evaluate real-world glycaemic outcomes of a tubeless hybrid closed-loop (HCL) insulin delivery system in type 1 diabetes (T1D), exploring the influence of ethnicity and socioeconomic status from a publicly funded system with universal access. MATERIALS AND
methodsThis was a retrospective observational study in adults with T1D initiating HCL (Omnipod® 5) at a large publicly funded multi-site diabetes service. Baseline glycaemic metrics were compared with 12-week post-initiation data. Clinical data and social determinants of health, such as ethnicity and socioeconomic deprivation indices, were analysed for subgroup differences.
resultsOne hundred and sixty adults with T1D were included (26.9% non-White; 48.8% in the two most deprived IMD quintiles). Mean time in range (%TIR; 3.9-10 mmol/L) improved from 52.7 ± 16% to 67.9 ± 12.7% (p < 0.001). Improvements were consistent across ethnic groups (mean % TIR +14.8% [95% CI: (12.6%, 17.3%)] and + 16.1% [95% CI: 12.4%, 19.7%] in White and non-White individuals, respectively, p = 0.488) and socioeconomic strata (mean % TIR + 15.9% [95% CI: 13.3%, 18.6%] and + 14.2% [95% CI: 11.2%, 17.1%] in those from lower and higher socioeconomic groups, respectively, p = 0.290). Those with poorer baseline glycaemia experienced greater improvements.
conclusionsEarly real-world use of a tubeless HCL system demonstrated significant and equal glycaemic improvements in diverse ethnic and socioeconomic groups. Promoting universal access to HCL technologies in T1D is therefore essential to ensure existing disparities in glycaemic outcomes are minimised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.